442 related articles for article (PubMed ID: 25943885)
21. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
[TBL] [Abstract][Full Text] [Related]
22. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
[TBL] [Abstract][Full Text] [Related]
23. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.
Kreiger PA; Okada Y; Simon S; Rorke LB; Louis DN; Golden JA
Acta Neuropathol; 2005 Apr; 109(4):387-92. PubMed ID: 15739101
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
[TBL] [Abstract][Full Text] [Related]
25. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
26. Oligodendroglioma: pathology and molecular biology.
Engelhard HH; Stelea A; Cochran EJ
Surg Neurol; 2002 Aug; 58(2):111-7; discussion 117. PubMed ID: 12453646
[TBL] [Abstract][Full Text] [Related]
27. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
[TBL] [Abstract][Full Text] [Related]
28. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Gadji M; Fortin D; Tsanaclis AM; Drouin R
Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
[TBL] [Abstract][Full Text] [Related]
29. A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component.
Gadji M; Crous-Tsanaclis AM; Mathieu D; Mai S; Fortin D; Drouin R
Neuropathology; 2014 Apr; 34(2):170-8. PubMed ID: 24118308
[TBL] [Abstract][Full Text] [Related]
30. Molecular markers in low-grade gliomas: predictive or prognostic?
Hartmann C; Hentschel B; Tatagiba M; Schramm J; Schnell O; Seidel C; Stein R; Reifenberger G; Pietsch T; von Deimling A; Loeffler M; Weller M;
Clin Cancer Res; 2011 Jul; 17(13):4588-99. PubMed ID: 21558404
[TBL] [Abstract][Full Text] [Related]
31. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
32. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
33. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.
Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H
Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of gliomas.
Appin CL; Brat DJ
Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
[TBL] [Abstract][Full Text] [Related]
36. Molecularly based management of gliomas in clinical practice.
Rudà R; Pellerino A; Magistrello M; Franchino F; Pinessi L; Soffietti R
Neurol Sci; 2015 Sep; 36(9):1551-7. PubMed ID: 26194534
[TBL] [Abstract][Full Text] [Related]
37. [The clinical relevance of 1p19q codeletion of oligodendrogliomas at the Department of Neurosurgery in Debrecen].
Klekner A; Fekete G; Rencsi M; Méhes G; Szabó P; Bognár L
Ideggyogy Sz; 2012 Jan; 65(1-2):17-24. PubMed ID: 22338842
[TBL] [Abstract][Full Text] [Related]
38. Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals.
Li YX; Aibaidula A; Shi Z; Chen H; Li KK; Chung NY; Yang RR; Chan DT; Poon WS; Lee KLR; Mao Y; Wu J; Chan AK; Zhou L; Ng HK
J Neurooncol; 2018 Sep; 139(2):307-322. PubMed ID: 29761369
[TBL] [Abstract][Full Text] [Related]
39. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
[TBL] [Abstract][Full Text] [Related]
40. Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components.
Hattab EM; Martin SE; Shapiro SA; Cheng L
J Neurosurg; 2011 Jun; 114(6):1648-53. PubMed ID: 21214337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
